免疫系统
癌症
无容量
易普利姆玛
癌症免疫疗法
临床试验
化疗
免疫原性细胞死亡
作者
Meghan J. Mooradian,Ryan J. Sullivan
出处
期刊:Future Oncology
[Future Medicine]
日期:2017-08-04
卷期号:13 (18): 1649-1663
被引量:6
标识
DOI:10.2217/fon-2017-0117
摘要
Recent advances in the use of immunotherapy have led to historic advancements in the field of oncology. Checkpoint inhibitors have demonstrated significant effectiveness against a broadening range of cancers. However, despite the success of antibodies against the immune regulators, CTLA4 and PD-L1/PD-1, only a subset of patients will have a durable response to these therapies, which implies that a broader view of cancer immunity is required. It is becoming increasingly apparent that combination therapy to target multiple events in the cancer-immunity cycle is needed and could potentially extend the benefit of immunotherapy to a larger population. In this review, we discuss the current status of immunotherapy and highlight the use of combination therapy to prime the tumor microenvironment and thereby improve treatment effect.
科研通智能强力驱动
Strongly Powered by AbleSci AI